Associations between the C-reactive protein-triglyceride-glucose index and its derived indices and the incidence and progression of cardiometabolic multimorbidity in participants with metabolic dysfunction-associated steatotic liver disease: a large-scale prospective cohort study Authors: Zhenyu Tian, Xuefang Yan, Fei Xue, Jianmin Yang, Na Li Published: 2026 ABSTRACT BackgroundThe C-reactive protein-triglyceride-glucose index (CTI), a composite biomarker reflecting insulin resistance and systemic inflammation, has been linked to metabolic dysfunction-associated steatotic liver disease (MASLD) and cardiometabolic diseases (CMDs). However, the role of CTI and its obesity-related derivatives in cardiometabolic multimorbidity (CMM) development and progression among MASLD patients remains unclear. The study evaluated associations of CTI-related indices with the incidence and progression of CMM, assessed their incremental predictive value, and explored potential biomarkers.MethodsThis cohort study included 109,181 UK Biobank participants with MASLD and without CMDs at baseline. CMM was defined as the coexistence of ≥ 2 CMDs, including type 2 diabetes mellitus (T2DM), ischemic heart disease (IHD), and stroke. Four CTI-related indices were calculated: CTI, CTI-body mass index (CTI-BMI), CTI-waist circumference (CTI-WC), and CTI-waist-to-height ratio (CTI-WHtR). Associations with CMM incidence and progression were analyzed using traditional Cox and multistate models. Predictive performance was assessed using the C-index, net reclassification improvement (NRI), and integrated discrimination improvement (IDI). Exploratory mediation analyses were conducted to examine whether metabolic, inflammatory, hepatic, and renal biomarkers statistically accounted for part of the associations.ResultsOver a median follow-up of 16 years, 4,219 participants developed CMM. All four indices were positively associated with incident CMM, with CTI-WHtR and CTI-WC showing more pronounced associations. Hazard ratios (HRs) (95% confidence interval) per 1-SD increase were 1.62 (1.58–1.66) for CTI-WHtR, 1.57 (1.53–1.61) for CTI-WC, 1.53 (1.49–1.57) for CTI-BMI, and 1.50 (1.45–1.54) for CTI (all P < 0.001). Multistate analyses indicated consistent positive associations with transitions from baseline to first CMD (FCMD) (HRs: 1.41–1.53), FCMD to CMM (HRs: 1.17–1.24), and CMM to death (HRs: 1.07–1.21), particularly for CTI-WHtR and CTI-WC. Subtype-specific analyses confirmed their pronounced associations, notably for T2DM incidence and IHD-to-CMM progression. Adding CTI-related indices to the conventional model resulted in modest but statistically significant improvements in predictive performance, with CTI-WC and CTI-WHtR showing the greatest improvements in the C-index, NRI, and IDI. Biomarkers of glycemic dysregulation, lipid metabolism, systemic inflammation, and organ dysfunction may partly account for the associations between CTI indices and incident CMM.ConclusionCTI-related indices, particularly CTI-WHtR and CTI-WC, were significantly associated with the incidence and progression of CMM in individuals with MASLD. These indices provided modest incremental predictive value and may serve as complementary markers for risk stratification. Further external validation and clinical utility assessment are needed before their routine use in clinical practice.Graphical abstract Supplementary InformationThe online version contains supplementary material available at 10.1186/s12933-026-03260-7. Research Insights What is currently known about this topic? CTI reflects insulin resistance and systemic inflammation.MASLD is closely linked to CMDs and CMM.CTI-related indices have been associated with MASLD, CMDs, and CMM. CTI reflects insulin resistance and systemic inflammation. CTI reflects insulin resistance and systemic inflammation. MASLD is closely linked to CMDs and CMM. MASLD is closely linked to CMDs and CMM. CTI-related indices have been associated with MASLD, CMDs, and CMM. CTI-related indices have been associated with MASLD, CMDs, and CMM. What is the key research question? Do CTI-related indices predict CMM onset and progression in MASLD?Do CTI-related indices predict CMM onset and progression in MASLD? Do CTI-related indices predict CMM onset and progression in MASLD? Do CTI-related indices predict CMM onset and progression in MASLD? Do CTI-related indices predict CMM onset and progression in MASLD? Do CTI-related indices predict CMM onset and progression in MASLD? What is new? All indices were associated with higher risks of CMM incidence and progression.CTI-WHtR and CTI-WC showed stronger links and superior predictive ability.Metabolism, inflammation, and organ dysfunction partly explained the associations. All indices were associated with higher risks of CMM incidence and progression. All indices were associated with higher risks of CMM incidence and progression. CTI-WHtR and CTI-WC showed stronger links and superior predictive ability. CTI-WHtR and CTI-WC showed stronger links and superior predictive ability. Metabolism, inflammation, and organ dysfunction partly explained the associations. Metabolism, inflammation, and organ dysfunction partly explained the associations. How might this study influence clinical practice? CTI-related indices, particularly CTI-WHtR and CTI-WC, may aid early CMM risk stratification in MASLD.These indices may support stage-specific CMM prevention strategies in MASLD. CTI-related indices, particularly CTI-WHtR and CTI-WC, may aid early CMM risk stratification in MASLD. CTI-related indices, particularly CTI-WHtR and CTI-WC, may aid early CMM risk stratification in MASLD. These indices may support stage-specific CMM prevention strategies in MASLD. These indices may support stage-specific CMM prevention strategies in MASLD. Introduction Metabolic dysfunction-associated steatotic liver disease (MASLD), previously referred to as nonalcoholic fatty liver disease, includes a range of liver abnormalities extending from isolated steatosis to metabolic dysfunction-associated steatohepatitis (MASH) and cirrhosis [1, 2]. It is now the leading form of chronic liver disease globally, affecting roughly 30%-40% of adults [3]. The condition is even more common in high-risk metabolic populations, with reported prevalence rates of 60%-70% in individuals with type 2 diabetes mellitus (T2DM) and 70%-80% in those with obesity [3]. As the global burden of metabolic disease continues to rise, the prevalence of MASLD is projected to exceed 55% by 2040 [3]. Increasing recognition of MASLD as a multisystem disease has shifted attention beyond hepatic outcomes [4], particularly because cardiovascular diseases (CVD) are the principal cause of mortality among affected patients [3, 5]. Recent studies further suggest that MASLD is associated with a markedly elevated burden of comorbidities [6], especially cardiometabolic multimorbidity (CMM) [7, 8], which refers to the presence of two or more cardiometabolic diseases (CMDs), typically including stroke, ischemic heart disease (IHD), and T2DM [9]. A likely biological link between MASLD and CMM is the accumulation of excessive and dysfunctional adipose tissue, which may promote chronic inflammation, endothelial dysfunction, insulin resistance (IR), and lipid metabolic dysregulation [10, 11]. Because pharmacological options for MASLD remain limited [12], identifying practical and reliable biomarkers that capture these pathogenic processes and predict the development and progression of CMM is an important priority for both clinical management and public health research. The triglyceride-glucose (TyG) index has been widely recognized as a reliable proxy for IR [13] and an important predictor of CMDs in individuals with MASLD [14–17]. Chronic low-grade inflammation is another key pathophysiological pathway linking MASLD and CMDs [3, 18], and C-reactive protein (CRP) is one of the most extensively validated inflammatory biomarkers for cardiometabolic risk prediction [19, 20]. These findings have promoted increasing interest in integrative markers that jointly capture metabolic dysfunction and inflammation. The C-reactive protein-triglyceride-glucose index (CTI) combines CRP and TyG into a single indicator of inflammatory-metabolic burden [21] and has been associated with elevated risks of CMDs and mortality, often demonstrating better predictive performance than either component alone [21–33]. However, several important gaps remain. First, most existing studies have focused on single cardiometabolic outcomes [21–32]. Although recent evidence has linked CTI to MASLD and mortality among individuals with MASLD [34–36], whether CTI is associated with incident CMM in this population remains unclear. Second, CMDs are not isolated conditions but may evolve through a dynamic process from a CMD-free state to first cardiometabolic disease (FCMD), CMM, and ultimately death. Therefore, analyses restricted to single disease endpoints may not fully capture the progression of cardiometabolic deterioration. Although CTI has been associated with CMM in the general population [37–42], evidence regarding its association with CMM incidence and progression trajectories among individuals with MASLD is still lacking. Third, given the central role of obesity in the pathogenesis of MASLD [3], CTI-derived indices incorporating adiposity measures may provide additional prognostic information beyond CTI alone. This possibility is supported by studies showing that TyG-based combinations with adiposity indices improve cardiometabolic risk prediction in MASLD [17, 43–46]. However, few studies have directly compared CTI with adiposity-integrated CTI indices for predicting incident CMM in this population. Fourth, MASLD is characterized by unfavorable biomarker profiles involving inflammation, metabolism, and multi-organ function [3, 47]. CTI and its components have also been associated with several of these biomarkers [34, 48–50], which are themselves related to CMM risk [51]. Nevertheless, whether these circulating biomarkers statistically account for part of the associations between CTI-related indices and incident CMM remains uncertain. To address these gaps, we leveraged data from a large-scale prospective cohort to examine the associations of CTI-related indices with the incidence and progression of CMM among individuals with MASLD. We further evaluated their incremental predictive performance for incident CMM and conducted exploratory mediation analyses to examine whether candidate blood biomarkers might statistically account for part of these associations. Methods Study participants The data analyzed in this study were derived from the UK Biobank, an ongoing large-scale prospective cohort of more than 500,000 middle-aged and older adults aged 37 to 73 years recruited from 22 assessment centers across England, Scotland, and Wales during 2006–2010. This resource was established to facilitate investigations into genetic, environmental, and lifestyle determinants of diseases in the general population. Baseline data collection included touchscreen questionnaires, standardized physical assessments, face-to-face interviews, medical diagnostic records, and biological samples, including blood, urine, and saliva. Together, these sources provide rich and multidimensional information on participants’ demographic characteristics, health status, behavioral factors, and biochemical indicators. Additional details regarding the study design and data collection protocols are available elsewhere [52]. Ethical approval was provided by the North West Multi-Centre Research Ethics Committee (reference: 21/NW/0157), and all participants gave written informed consent. This study was conducted under the UK Biobank application number 151,350. From the initial UK Biobank cohort of 502,112 participants, we excluded 354,661 individuals who did not have MASLD at baseline, yielding 147,451 participants for further assessment. Participants with missing CTI-related indices were then excluded (n = 12,007), leaving 135,444 individuals. We additionally removed 18,997 participants with baseline IHD, stroke, or T2DM, resulting in 116,447 participants without CMDs at baseline. Finally, after excluding 7,266 individuals with missing covariate data, 109,181 participants remained for the main association analysis (Fig. 1). Fig. 1Flowchart of participant selection. Abbreviations: CTI, C-reactive protein-triglyceride-glucose index; CMD, cardiometabolic disease; IHD, ischemic heart disease; T2DM, type 2 diabetes mellitus; MASLD, metabolic dysfunction-associated steatotic liver disease. Flowchart of participant selection. Abbreviations: CTI, C-reactive protein-triglyceride-glucose index; CMD, cardiometabolic disease; IHD, ischemic heart disease; T2DM, type 2 diabetes mellitus; MASLD, metabolic dysfunction-associated steatotic liver disease. Definition of individuals with MASLD at baseline Following the international consensus definition [3], MASLD at baseline was defined as hepatic steatosis in the presence of at least one metabolic risk factor. Because liver histology and imaging data were not available for the entire eligible UK Biobank cohort at baseline [17, 53], hepatic steatosis was operationally identified using a fatty liver index (FLI) score ≥ 60 [54]. The FLI is a validated, non-invasive surrogate marker for hepatic steatosis that has demonstrated reliable diagnostic performance in previous studies [54]. This FLI-based approach for identifying hepatic steatosis and defining baseline MASLD has been applied in previous epidemiological studies using the UK Biobank [17, 53, 55]. Therefore, this approach enabled the application of a uniform and previously established definition of hepatic steatosis across the large analytical cohort and facilitated comparability with previous UK Biobank-based findings. According to the consensus definition [3], cardiometabolic risk factors include overweight or abdominal obesity, hyperglycemia, elevated blood pressure, hypertriglyceridemia, and low high-density lipoprotein cholesterol (HDL-C). Consistent with previous studies based on the UK Biobank [53, 55], overweight or abdominal obesity was defined as a body mass index (BMI) ≥ 25 kg/m2 or a waist circumference (WC) ≥ 90 cm in men and ≥ 80 cm in women; elevated blood pressure as ≥ 130/85 mmHg or use of antihypertensive medications; hypertriglyceridemia as triglycerides (TG) ≥ 1.70 mmol/L or use of lipid-lowering medications; low HDL-C as ≤ 1.0 mmol/L in men or ≤ 1.3 mmol/L in women, or use of lipid-lowering medications; and hyperglycemia as glycated hemoglobin (HbA1c) ≥ 39 mmol/mol, fasting serum glucose ≥ 5.6 mmol/L, 2-hour postprandial glucose ≥ 7.8 mmol/L, a diagnosis of T2DM, or use of antidiabetic medications. Because participants with T2DM at baseline were excluded from the present study, criteria directly related to prevalent T2DM were not applicable to the baseline MASLD definition. Moreover, individuals with excessive alcohol intake or chronic viral hepatitis (hepatitis B or C) were excluded from the MASLD definition [53, 55]. Assessment of CTI-related indices Peripheral venous blood samples were collected from UK Biobank participants at baseline for biomarker assessment. Further details on sample collection, processing, and biomarker measurement have been described previously [56]. In short, all collected biological samples were processed, fractionated, and stored at − 80 °C until analysis. At baseline, a wide range of blood biomarkers, including hematological indices and biochemical markers, was measured in approximately 500,000 participants. Hematological parameters were analyzed in EDTA-anticoagulated samples using Beckman Coulter LH750 analyzers, which enabled automated cell counting and leukocyte differentiation. Biochemical markers, including TG, serum glucose, and CRP, were quantified using immunoassay and clinical chemistry analyzers. Comprehensive quality control procedures were applied to ensure high data accuracy and reliability. Following previous studies [39, 45, 57], CTI and its obesity-related derivatives were calculated as follows: CTI = 0.412 × ln [CRP (mg/L)] + ln (TG (mg/dL) × glucose (mg/dL)/2); CTI-BMI = \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$ {\mathrm{CTI}} \times \frac{{weight\left( {{\mathrm{kg}}} \right)}}{{height\left( {\mathrm{m}} \right)^{2} }} $$\end{document}; CTI-WC = \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$ {\mathrm{CTI}} \times WC\left( {{\mathrm{cm}}} \right) $$\end{document};CTI-WHtR = \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$ {\mathrm{CTI}} \times \frac{{WC\left( {{\mathrm{cm}}} \right)}}{{height\left( {{\mathrm{cm}}} \right)}} $$\end{document}; CTI = 0.412 × ln [CRP (mg/L)] + ln (TG (mg/dL) × glucose (mg/dL)/2); CTI = 0.412 × ln [CRP (mg/L)] + ln (TG (mg/dL) × glucose (mg/dL)/2); CTI-BMI = \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$ {\mathrm{CTI}} \times \frac{{weight\left( {{\mathrm{kg}}} \right)}}{{height\left( {\mathrm{m}} \right)^{2} }} $$\end{document}; CTI-BMI = \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$ {\mathrm{CTI}} \times \frac{{weight\left( {{\mathrm{kg}}} \right)}}{{height\left( {\mathrm{m}} \right)^{2} }} $$\end{document}; CTI-WC = \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$ {\mathrm{CTI}} \times WC\left( {{\mathrm{cm}}} \right) $$\end{document}; CTI-WC = \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$ {\mathrm{CTI}} \times WC\left( {{\mathrm{cm}}} \right) $$\end{document}; CTI-WHtR = \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$ {\mathrm{CTI}} \times \frac{{WC\left( {{\mathrm{cm}}} \right)}}{{height\left( {{\mathrm{cm}}} \right)}} $$\end{document}; CTI-WHtR = \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$ {\mathrm{CTI}} \times \frac{{WC\left( {{\mathrm{cm}}} \right)}}{{height\left( {{\mathrm{cm}}} \right)}} $$\end{document}; Blood biomarkers To examine candidate biomarkers potentially involved in the relationship between CTI-related indices and incident CMM in individuals with MASLD, we assessed a panel of blood-based markers identified from prior studies [34, 48–51]. The selected markers covered both blood cell indices and biochemical measures and were organized into four groups. The liver function group included albumin, alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyltransferase (GGT), total bilirubin (TB), and total protein (TP). The kidney function group included urea, creatinine, cystatin C, and urate. The inflammatory group consisted of white blood cell (WBC) count, counts of platelets, lymphocytes, monocytes, neutrophils, eosinophils, and basophils. The metabolic group covered apolipoprotein A (ApoA), apolipoprotein B (ApoB), total cholesterol (TC), HbA1c, LDL-C, HDL-C, insulin-like growth factor 1 (IGF-1), and lipoprotein A. Further details on the selected biomarkers are provided in Table S1. Ascertainment of CMM Incident CMM was the primary outcome and was defined as the coexistence of at least two CMDs among individuals with MASLD. Consistent with previous studies [39, 50], the primary definition of CMDs included three major cardiometabolic conditions: T2DM, stroke, and IHD. These conditions were identified according to the International Classification of Diseases, Tenth Revision (ICD-10) codes, including E11 for T2DM, I60-I64 and I69 for stroke, and I20-I25 for IHD. Disease onset was ascertained using the UK Biobank First Occurrence fields (Category ID: 1712), which integrate multiple sources of health-related information, primarily including hospital admissions, primary care records, and death registrations, with self-reported medical conditions used as supplementary information. CMDs were identified using predefined ICD-10 codes to ensure standardized classification of outcomes across the cohort. The earliest recorded date of each CMD was used to define disease onset and subsequent transition states in the multistate models. The incident date of CMM was defined as the date on which the second CMD was diagnosed. Hospital admission data were obtained via linkage to national inpatient databases [52]. All-cause deaths were ascertained through linkage to national death registries, with mortality data obtained from the National Health Service (NHS) Information Centre for England and Wales and the NHS Central Register for Scotland [52]. Follow-up was calculated from baseline recruitment to the earliest occurrence of second CMD diagnosis, death, loss to follow-up, or the end of follow-up on August 31, 2025. Covariates Covariates were determined a priori from the literature and included demographic, socioeconomic, and lifestyle factors that could influence the development of CMDs [9, 39, 50, 58]. The variables considered were age (years), sex, ethnicity (White vs. non-White), Townsend Deprivation Index (TDI), educational attainment (college degree or above vs. lower), employment status (employed, retired, or unemployed), smoking status (never, former, or current), frequency of alcohol consumption (never, special occasions only, 1–3 times/month, 1–2 times/week, 3–4 times/week, or daily/almost daily), physical activity (adequate vs. inadequate), sedentary behavior (< 4 h/day vs. others), and sleep duration (7–9 h/day vs. others). TDI was included as a continuous marker of area-level deprivation derived from unemployment, non-car ownership, non-home ownership, and household overcrowding, with higher scores indicating greater socioeconomic disadvantage [58]. Adequate physical activity was defined according to established criteria: ≥75 min/week of vigorous activity, ≥ 150 min/week of moderate activity, an equivalent combination of the two, moderate activity ≥ 5 times/week, or vigorous activity ≥ 1 time/week [59]. In line with prior reports [58], sedentary behavior was defined as ≥ 4 h/day of television viewing and unhealthy sleep duration as < 7 h or > 9 h/day. Missing covariate data led to exclusion from the primary analysis, whereas multiple imputation was used in sensitivity analyses. The proportion of missing values is provided in Table S2, and detailed descriptions of all covariates are presented in Table S3. Statistical analyses Baseline characteristics were summarized by CMM status (yes vs. no) or by CTI quartiles (Q1-Q4). Continuous variables are reported as mean (standard deviations, SD), and categorical variables as counts (percentages). Comparisons of continuous variables were performed using t tests (for two groups) or analysis of variance (ANOVA) (for three or more groups), and categorical variables were evaluated using chi-square tests. Cox proportional hazards models were used to assess the relationships between CTI-related indices and the risk of incident CMM among individuals with MASLD, with follow-up duration serving as the time scale. The proportional hazards assumption was tested using Schoenfeld residuals and was not violated. Associations were quantified as hazard ratios (HRs) with 95% confidence intervals (CIs), considering both continuous exposures (per SD increase) and categorical exposures defined by quartiles (reference: Q1). Trend analyses were conducted by modeling quartiles as an ordinal continuous variable. Three hierarchical models were specified: Model 1 adjusted for demographic variables, including age, sex, and ethnicity; Model 2 additionally included socioeconomic indicators, including TDI, educational levels, and employment status; and Model 3 further incorporated lifestyle factors, including smoking status, drinking frequency, physical activity, sedentary behavior, and sleep duration. Kaplan-Meier curves and log-rank tests were used to compare cumulative incidence across exposure groups. Restricted cubic spline (RCS) analyses with four knots (at the 5th, 35th, 65th, and 95th percentiles) were conducted based on Model 3 to explore dose-response patterns. To investigate the impact of CTI-related indices across disease stages, we utilized multi-state models, which extend traditional competing risks models. By treating multiple subsequent or competing outcomes as distinct states, this method facilitates simultaneous evaluation of stage-specific associations while accounting for competing risks [60]. Based on the natural progression of CMM and earlier studies [9, 39], five transitions were defined in the overall transition pattern (Fig. 2A): (A) baseline to FCMD, (B) baseline to death, (C) FCMD to CMM, (D) FCMD to death, and (E) CMM to death. To further explore disease-specific heterogeneity, FCMD was stratified into three subtypes, including T2DM, stroke, and IHD, resulting in 11 specific transitions (Fig. 2B): (A1) baseline to T2DM, (A2) baseline to stroke, (A3) baseline to IHD, (A4) baseline to death, (B1) T2DM to CMM, (B2) T2DM to death, (C1) stroke to CMM, (C2) stroke to death, (D1) IHD to CMM, (D2) IHD to death, and (E) CMM to death. All models were adjusted for covariates in Model 3. When multiple disease stages occurred on the same date, the earlier stage was assigned an entry time 0.5 days prior to the subsequent stage [9]. Fig. 2Progression trajectories of CMM among participants with MASLD. Abbreviations: CMM, cardiometabolic multimorbidity; FCMD, first cardiometabolic disease; IHD, ischemic heart disease; MASLD, metabolic dysfunction-associated steatotic liver disease; T2DM, type 2 diabetes mellitus Progression trajectories of CMM among participants with MASLD. Abbreviations: CMM, cardiometabolic multimorbidity; FCMD, first cardiometabolic disease; IHD, ischemic heart disease; MASLD, metabolic dysfunction-associated steatotic liver disease; T2DM, type 2 diabetes mellitus In line with prior studies [17, 39, 50], two nested models were developed to evaluate whether CTI-related indices provided incremental predictive information for incident CMM beyond the base model. The base model comprised the factors included in Model 3, while the extended model additionally incorporated each CTI-related index individually. Improvements in predictive performance were quantified using the net reclassification index (NRI), integrated discrimination improvement (IDI), and the concordance index (C-index) [61, 62]. Specifically, NRI and IDI reflect changes in risk reclassification and discrimination, respectively, whereas the C-index measures overall model discrimination. Additionally, the C-index of each CTI-related index itself for predicting the risk of incident CMM was calculated to evaluate its predictive performance. Pairwise comparisons among the calculated C-index values were then conducted using the ‘compareC’ R package to further evaluate whether any index showed relatively better performance [63]. These metrics were used to assess statistical improvement in model performance rather than to establish clinical utility. Furthermore, receiver operating characteristic (ROC) curve analyses were performed to identify the optimal cutoff values of CTI-related indices for incident CMM. The optimal cutoff point for each index was determined using the Youden index. To further compare the predictive value of CTI-related indices with an existing clinical risk assessment tool, we conducted an additional incremental prediction analysis using SCORE2 as the base model [64], with each CTI-related index added individually to the SCORE2-based model. We performed exploratory mediation analyses to assess whether selected biomarkers might statistically account for part of the associations between CTI-related indices and incident CMM among individuals with MASLD. Following established analytical frameworks [50, 65], a two-stage procedure was used to identify candidate biomarkers related to inflammation, liver and kidney function, and metabolism. In the first stage, multivariable-adjusted linear regression models (Model 3) were applied to assess associations between CTI-related indices and individual biomarkers. In the second stage, fully adjusted Cox proportional hazards models were used to evaluate the associations between each biomarker and incident CMM. Biomarkers that were significant in both stages and exhibited consistent association directions were included in the exploratory mediation analysis [50, 65, 66]. Mediation analyses were conducted using the ‘CMAverse’ R package within a Cox regression-based framework to decompose the total effect into natural direct and indirect effects and to estimate the proportion mediated (PM) by biomarkers, with all estimates expressed on the HR scale [66, 67]. All biomarker variables were standardized before analysis to facilitate comparability across biomarkers. Statistical inference for mediation analyses was based on 1,000 nonparametric bootstrap resamples. In each bootstrap iteration, participants were resampled with replacement from the analytic sample to generate a dataset of the same size as the original dataset, and the full Cox regression-based mediation model was refitted. Bootstrap distributions were then used to derive the 95% CIs for each effect and PM. False discovery rate (FDR) correction was performed using the Benjamini-Hochberg procedure, and an FDR-adjusted P value < 0.05 was considered statistically significant in these biomarker analyses. Given the observational nature of the study and the single baseline measurement of CTI-related indices and biomarkers, the mediation analyses were considered exploratory and should not be interpreted as establishing causal pathways. We conducted a series of sensitivity analyses to verify the robustness of the observed associations. First, to mitigate reverse causality, individuals who developed CMM within the first 5 years were excluded. Second, missing covariate data were imputed using chained equations with the ‘mice’ R package. Five imputed datasets were generated with 20 iterations to ensure convergence and stability of the imputation process, and estimates from Cox proportional hazards models were pooled across imputed datasets using Rubin’s rules. Third, Fine-Gray competing risk models were used to account for death from other causes. Fourth, to assess the potential influence of pharmacological, dietary, familial, and genetic factors, we further adjusted for baseline use of hypoglycemic and lipid-lowering medications, healthy diet score, genetic risk, and family history of CMDs. Fifth, we repeated the association analyses using a broader CMM definition that additionally included hypertension, redefining CMM as the coexistence of at least two conditions among T2DM, IHD, stroke, and hypertension [68, 69]. Subgroup analyses stratified by sociodemographic characteristics were also performed to examine consistency across strata. All analyses were carried out using R software (version 4.4.0). Except for biomarker analyses, a two-sided P value < 0.05 was considered statistically significant. Results Baseline characteristics As shown in Table 1, the 109,181 participants with MASLD had a mean age of 56.7 years (SD: 7.9), and 40.1% were women. Baseline characteristics differed significantly between participants who developed CMM and those who did not (all P < 0.001). The CMM group was more likely to be older, male, non-White, less educated, unemployed, and socioeconomically disadvantaged, and to exhibit unfavorable lifestyle behaviors, including inadequate physical activity, smoking, irregular sleep, and long sedentary time. Additionally, all baseline CTI-related indices were significantly higher among individuals with incident CMM. Baseline characteristics according to quartiles of baseline CTI are shown in Table S4. Table 1Baseline characteristics of the study populationCharacteristicsTotal populationCMM occurrenceP valueNoYes n 109,181104,9624,219Age, year56.7 ± 7.956.6 ± 7.960.2 ± 6.9< 0.001Sex< 0.001 Female43,820 (40.1)42,423 (40.4)1,397 (33.1) Male65,361 (59.9)62,539 (59.6)2,822 (66.9)Ethnicity< 0.001 Whites103,462 (94.8)99,577 (94.9)3,885 (92.1) Non-Whites5,719 (5.2)5,385 (5.1)334 (7.9)Employment status< 0.001 Working64,472 (59.1)62,656 (59.7)1,816 (43.0) Retired35,474 (32.5)33,590 (32.0)1,884 (44.7) Unemployed9,235 (8.5)8,716 (8.3)519 (12.3)Educational levels< 0.001 University or college31,920 (29.2)31,039 (29.6)881 (20.9) Others77,261 (70.8)73,923 (70.4)3,338 (79.1)Townsend deprivation index-1.3 ± 3.1-1.3 ± 3.1-0.6 ± 3.4< 0.001Frequency of drinking< 0.001 Daily or almost daily13,352 (12.2)12,933 (12.3)419 (9.9) 3–4 times/week23,901 (21.9)23,185 (22.1)716 (17.0) 1–2 times/week32,765 (30.0)31,605 (30.1)1,160 (27.5) 1–3 times/month14,752 (13.5)14,175 (13.5)577 (13.7) Special occasions only14,966 (13.7)14,217 (13.5)749 (17.8) Never9,445 (8.7)8,847 (8.4)598 (14.2)Smoking status< 0.001 Never smoking58,462 (53.5)56,674 (54.0)1,788 (42.4) Ever smoking40,151 (36.8)38,319 (36.5)1,832 (43.4) Current smoking10,568 (9.7)9,969 (9.5)599 (14.2)Sleep duration< 0.001 7–9 h/day77,736 (71.2)74,967 (71.4)2,769 (65.6) Others31,445 (28.8)29,995 (28.6)1,450 (34.4)Physical activity< 0.001 Inadequate34,801 (31.9)33,298 (31.7)1,503 (35.6) Adequate74,380 (68.1)71,664 (68.3)2,716 (64.4)Sedentary behavior< 0.001 < 4 h/day71,249 (65.3)68,890 (65.6)2,359 (55.9) ≥ 4 h/day37,932 (34.7)36,072 (34.4)1,860 (44.1)CTI9.4 ± 0.69.4 ± 0.69.7 ± 0.7< 0.001CTI-WC958.3 ± 113.8955.5 ± 112.01,028.1 ± 135.1< 0.001CTI-BMI296.0 ± 48.0295.1 ± 47.5316.6 ± 55.6< 0.001CTI-WHtR5.6 ± 0.75.6 ± 0.76.1 ± 0.8< 0.001Data are presented as mean ± standard deviation for continuous variables and n (%) for categorical variables.BMI, body mass index; CMM, cardiometabolic multimorbidity; CTI, C-reactive protein-triglyceride-glucose index; WC, waist circumference; WHtR, waist-to-height ratio Table 1Baseline characteristics of the study populationCharacteristicsTotal populationCMM occurrenceP valueNoYes n 109,181104,9624,219Age, year56.7 ± 7.956.6 ± 7.960.2 ± 6.9< 0.001Sex< 0.001 Female43,820 (40.1)42,423 (40.4)1,397 (33.1) Male65,361 (59.9)62,539 (59.6)2,822 (66.9)Ethnicity< 0.001 Whites103,462 (94.8)99,577 (94.9)3,885 (92.1) Non-Whites5,719 (5.2)5,385 (5.1)334 (7.9)Employment status< 0.001 Working64,472 (59.1)62,656 (59.7)1,816 (43.0) Retired35,474 (32.5)33,590 (32.0)1,884 (44.7) Unemployed9,235 (8.5)8,716 (8.3)519 (12.3)Educational levels< 0.001 University or college31,920 (29.2)31,039 (29.6)881 (20.9) Others77,261 (70.8)73,923 (70.4)3,338 (79.1)Townsend deprivation index-1.3 ± 3.1-1.3 ± 3.1-0.6 ± 3.4< 0.001Frequency of drinking< 0.001 Daily or almost daily13,352 (12.2)12,933 (12.3)419 (9.9) 3–4 times/week23,901 (21.9)23,185 (22.1)716 (17.0) 1–2 times/week32,765 (30.0)31,605 (30.1)1,160 (27.5) 1–3 times/month14,752 (13.5)14,175 (13.5)577 (13.7) Special occasions only14,966 (13.7)14,217 (13.5)749 (17.8) Never9,445 (8.7)8,847 (8.4)598 (14.2)Smoking status< 0.001 Never smoking58,462 (53.5)56,674 (54.0)1,788 (42.4) Ever smoking40,151 (36.8)38,319 (36.5)1,832 (43.4) Current smoking10,568 (9.7)9,969 (9.5)599 (14.2)Sleep duration< 0.001 7–9 h/day77,736 (71.2)74,967 (71.4)2,769 (65.6) Others31,445 (28.8)29,995 (28.6)1,450 (34.4)Physical activity< 0.001 Inadequate34,801 (31.9)33,298 (31.7)1,503 (35.6) Adequate74,380 (68.1)71,664 (68.3)2,716 (64.4)Sedentary behavior< 0.001 < 4 h/day71,249 (65.3)68,890 (65.6)2,359 (55.9) ≥ 4 h/day37,932 (34.7)36,072 (34.4)1,860 (44.1)CTI9.4 ± 0.69.4 ± 0.69.7 ± 0.7< 0.001CTI-WC958.3 ± 113.8955.5 ± 112.01,028.1 ± 135.1< 0.001CTI-BMI296.0 ± 48.0295.1 ± 47.5316.6 ± 55.6< 0.001CTI-WHtR5.6 ± 0.75.6 ± 0.76.1 ± 0.8< 0.001Data are presented as mean ± standard deviation for continuous variables and n (%) for categorical variables.BMI, body mass index; CMM, cardiometabolic multimorbidity; CTI, C-reactive protein-triglyceride-glucose index; WC, waist circumference; WHtR, waist-to-height ratio Baseline characteristics of the study population Data are presented as mean ± standard deviation for continuous variables and n (%) for categorical variables. BMI, body mass index; CMM, cardiometabolic multimorbidity; CTI, C-reactive protein-triglyceride-glucose index; WC, waist circumference; WHtR, waist-to-height ratio Prospective associations of CTI-related indices with incident CMM During a median follow-up of 16.0 years (interquartile range: 14.1–17.0 years), 4,219 participants (3.9%) developed incident CMM. Kaplan-Meier curves showed a graded increase in the cumulative incidence of CMM across quartiles of CTI-related indices, with the highest quartile consistently showing the greatest risk (all log-rank P < 0.001; Fig. 3). Multivariable-adjusted RCS analyses demonstrated positive and nonlinear dose–response associations between CTI-related indices and incident CMM, with steeper risk increases observed at higher exposure levels (P for overall < 0.001; P for nonlinearity < 0.05; Fig. 4). Cox regression analyses showed that all four CTI-related indices were significantly associated with a higher risk of incident CMM, with the strongest association observed for CTI-WHtR, followed by CTI-WC (Table 2). The HRs (95% CIs) per SD increase were as follows: 1.62 (1.58–1.66) for CTI-WHtR, 1.57 (1.53–1.61) for CTI-WC, 1.53 (1.49–1.57) for CTI-BMI, and 1.50 (1.45–1.54) for CTI (all P < 0.001). Similar graded associations were observed in quartile-based analyses. Compared with participants in the lowest quartile, those in the highest quartile had markedly higher risks of CMM (all P for trend < 0.001). Overall, CTI-WHtR and CTI-WC showed the most pronounced associations with incident CMM. Fig. 3Cumulative hazard curves for incident CMM across quartiles of CTI-related indices among participants with MASLD. Abbreviations: CMM, cardiometabolic multimorbidity; CTI, C-reactive protein-triglyceride-glucose index; MASLD, metabolic dysfunction-associated steatotic liver disease; BMI, body mass index; WC, waist circumference; WHtR, waist-to-height ratio. Cumulative hazard curves for incident CMM across quartiles of CTI-related indices among participants with MASLD. Abbreviations: CMM, cardiometabolic multimorbidity; CTI, C-reactive protein-triglyceride-glucose index; MASLD, metabolic dysfunction-associated steatotic liver disease; BMI, body mass index; WC, waist circumference; WHtR, waist-to-height ratio. Fig. 4Dose–response associations of CTI-related indices with incident CMM among participants with MASLD. Notes: Models were adjusted for age, sex, ethnicity, employment status, educational levels, Townsend deprivation index, drinking frequency, smoking status, sleep duration, physical activity, and sedentary behavior Dose–response associations of CTI-related indices with incident CMM among participants with MASLD. Notes: Models were adjusted for age, sex, ethnicity, employment status, educational levels, Townsend deprivation index, drinking frequency, smoking status, sleep duration, physical activity, and sedentary behavior Table 2Associations of CTI-related indices with risk of CMM among participants with MASLDCategoryIncidence rateModel 1Model 2Model 3HR (95% CI)P valueHR (95% CI)P valueHR (95% CI)P valueCTI Quartile 11.561.00 (Ref.)1.00 (Ref.)1.00 (Ref.) Quartile 21.831.19 (1.08–1.32)0.0011.19 (1.07–1.32)0.0011.17 (1.05–1.29)0.004 Quartile 32.331.54 (1.39–1.70)< 0.0011.51 (1.36–1.66)< 0.0011.44 (1.31–1.59)< 0.001 Quartile 44.232.88 (2.63–3.15)< 0.0012.73 (2.50–2.99)< 0.0012.52 (2.30–2.76)< 0.001 P-trend< 0.001< 0.001< 0.001 Per 1-SD increase1.59 (1.54–1.63)< 0.0011.55 (1.50–1.59)< 0.0011.50 (1.45–1.54)< 0.001CTI-WC Quartile 11.111.00 (Ref.)1.00 (Ref.)1.00 (Ref.) Quartile 21.651.38 (1.23–1.55)< 0.0011.36 (1.21–1.53)< 0.0011.32 (1.17–1.48)< 0.001 Quartile 32.432.00 (1.80–2.23)< 0.0011.94 (1.74–2.16)< 0.0011.82 (1.64–2.03)< 0.001 Quartile 44.804.14 (3.74–4.57)< 0.0013.82 (3.46–4.23)< 0.0013.45 (3.12–3.82)< 0.001 P-trend< 0.001< 0.001< 0.001 Per 1-SD increase1.67 (1.63–1.71)< 0.0011.62 (1.58–1.66)< 0.0011.57 (1.53–1.61)< 0.001CTI-BMI Quartile 11.371.00 (Ref.)1.00 (Ref.)1.00 (Ref.) Quartile 21.971.58 (1.42–1.75)< 0.0011.53 (1.38–1.70)< 0.0011.49 (1.34–1.65)< 0.001 Quartile 32.542.32 (2.09–2.57)< 0.0012.19 (1.98–2.43)< 0.0012.07 (1.87–2.29)< 0.001 Quartile 44.034.40 (3.99–4.85)< 0.0014.00 (3.63–4.41)< 0.0013.64 (3.30–4.02)< 0.001 P-trend< 0.001< 0.001< 0.001 Per 1-SD increase1.63 (1.59–1.67)< 0.0011.58 (1.54–1.62)< 0.0011.53 (1.49–1.57)< 0.001CTI-WHtR Quartile 11.071.00 (Ref.)1.00 (Ref.)1.00 (Ref.) Quartile 21.721.57 (1.39–1.76)< 0.0011.52 (1.35–1.70)< 0.0011.46 (1.30–1.64)< 0.001 Quartile 32.372.21 (1.98–2.47)< 0.0012.08 (1.86–2.32)< 0.0011.95 (1.74–2.18)< 0.001 Quartile 44.824.93 (4.45–5.46)< 0.0014.43 (4.00-4.92)< 0.0013.99 (3.59–4.43)< 0.001 P-trend< 0.001< 0.001< 0.001 Per 1-SD increase1.73 (1.69–1.77)< 0.0011.67 (1.63–1.72)< 0.0011.62 (1.58–1.66)< 0.001Incidence rates are presented per 1,000 person-yearsModel 1 was adjusted for age, sex, and ethnicityModel 2 was further adjusted for employment status, educational levels, and Townsend deprivation indexModel 3 was additionally adjusted for frequency of drinking, smoking status, sleep duration, physical activity, and sedentary behaviorMASLD, metabolic dysfunction-associated steatotic liver disease; BMI, body mass index; CI, confidence interval; CMM, cardiometabolic multimorbidity; CTI, C-reactive protein-triglyceride-glucose index; HR, hazard ratio; WC, waist circumference; WHtR, waist-to-height ratio Table 2Associations of CTI-related indices with risk of CMM among participants with MASLDCategoryIncidence rateModel 1Model 2Model 3HR (95% CI)P valueHR (95% CI)P valueHR (95% CI)P valueCTI Quartile 11.561.00 (Ref.)1.00 (Ref.)1.00 (Ref.) Quartile 21.831.19 (1.08–1.32)0.0011.19 (1.07–1.32)0.0011.17 (1.05–1.29)0.004 Quartile 32.331.54 (1.39–1.70)< 0.0011.51 (1.36–1.66)< 0.0011.44 (1.31–1.59)< 0.001 Quartile 44.232.88 (2.63–3.15)< 0.0012.73 (2.50–2.99)< 0.0012.52 (2.30–2.76)< 0.001 P-trend< 0.001< 0.001< 0.001 Per 1-SD increase1.59 (1.54–1.63)< 0.0011.55 (1.50–1.59)< 0.0011.50 (1.45–1.54)< 0.001CTI-WC Quartile 11.111.00 (Ref.)1.00 (Ref.)1.00 (Ref.) Quartile 21.651.38 (1.23–1.55)< 0.0011.36 (1.21–1.53)< 0.0011.32 (1.17–1.48)< 0.001 Quartile 32.432.00 (1.80–2.23)< 0.0011.94 (1.74–2.16)< 0.0011.82 (1.64–2.03)< 0.001 Quartile 44.804.14 (3.74–4.57)< 0.0013.82 (3.46–4.23)< 0.0013.45 (3.12–3.82)< 0.001 P-trend< 0.001< 0.001< 0.001 Per 1-SD increase1.67 (1.63–1.71)< 0.0011.62 (1.58–1.66)< 0.0011.57 (1.53–1.61)< 0.001CTI-BMI Quartile 11.371.00 (Ref.)1.00 (Ref.)1.00 (Ref.) Quartile 21.971.58 (1.42–1.75)< 0.0011.53 (1.38–1.70)< 0.0011.49 (1.34–1.65)< 0.001 Quartile 32.542.32 (2.09–2.57)< 0.0012.19 (1.98–2.43)< 0.0012.07 (1.87–2.29)< 0.001 Quartile 44.034.40 (3.99–4.85)< 0.0014.00 (3.63–4.41)< 0.0013.64 (3.30–4.02)< 0.001 P-trend< 0.001< 0.001< 0.001 Per 1-SD increase1.63 (1.59–1.67)< 0.0011.58 (1.54–1.62)< 0.0011.53 (1.49–1.57)< 0.001CTI-WHtR Quartile 11.071.00 (Ref.)1.00 (Ref.)1.00 (Ref.) Quartile 21.721.57 (1.39–1.76)< 0.0011.52 (1.35–1.70)< 0.0011.46 (1.30–1.64)< 0.001 Quartile 32.372.21 (1.98–2.47)< 0.0012.08 (1.86–2.32)< 0.0011.95 (1.74–2.18)< 0.001 Quartile 44.824.93 (4.45–5.46)< 0.0014.43 (4.00-4.92)< 0.0013.99 (3.59–4.43)< 0.001 P-trend< 0.001< 0.001< 0.001 Per 1-SD increase1.73 (1.69–1.77)< 0.0011.67 (1.63–1.72)< 0.0011.62 (1.58–1.66)< 0.001Incidence rates are presented per 1,000 person-yearsModel 1 was adjusted for age, sex, and ethnicityModel 2 was further adjusted for employment status, educational levels, and Townsend deprivation indexModel 3 was additionally adjusted for frequency of drinking, smoking status, sleep duration, physical activity, and sedentary behaviorMASLD, metabolic dysfunction-associated steatotic liver disease; BMI, body mass index; CI, confidence interval; CMM, cardiometabolic multimorbidity; CTI, C-reactive protein-triglyceride-glucose index; HR, hazard ratio; WC, waist circumference; WHtR, waist-to-height ratio Associations of CTI-related indices with risk of CMM among participants with MASLD Incidence rates are presented per 1,000 person-years Model 1 was adjusted for age, sex, and ethnicity Model 2 was further adjusted for employment status, educational levels, and Townsend deprivation index Model 3 was additionally adjusted for frequency of drinking, smoking status, sleep duration, physical activity, and sedentary behavior MASLD, metabolic dysfunction-associated steatotic liver disease; BMI, body mass index; CI, confidence interval; CMM, cardiometabolic multimorbidity; CTI, C-reactive protein-triglyceride-glucose index; HR, hazard ratio; WC, waist circumference; WHtR, waist-to-height ratio Associations between CTI-related indices and the progression trajectory of CMM Among 109,181 participants with MASLD, 26,362 (24.1%) developed FCMD during follow-up, of whom 4,219 (16.0%) subsequently progressed to CMM. A total of 12,456 deaths were recorded, including 4,406 deaths after FCMD onset and 1,376 after CMM onset (Table 3). In multistate models, higher CTI-related indices were consistently associated with increased risks of transition from baseline to FCMD, from FCMD to CMM, and from CMM to death (Table 3). For the transition from baseline to FCMD, CTI-WHtR showed the strongest association [HR (95% CI): 1.53 (1.51–1.55)], followed by CTI-WC [HR (95% CI): 1.51 (1.49–1.52)]. CTI-WHtR and CTI-WC generally showed stronger associations across disease-progression transitions, particularly for the baseline-to-FCMD and FCMD-to-CMM transitions. Associations with mortality after FCMD were comparatively modest. Table 3Roles of CTI-related indices in transitions from healthy status to FCMD, CMM, and death among participants with MASLDExposureHR (95% CI)Transition AHealthy to FCMDTransition BHealthy to deathTransition CFCMD to CMMTransition DFCMD to deathTransition ECMM to deathNo. of transitions26,362/109,1816,674/109,1814,219/26,3624,406/26,3621,376/4,219Proportion, %24.26.116.016.732.6CTI1.41 (1.39–1.43)***1.11 (1.08–1.13)***1.17 (1.14–1.20)***0.98 (0.95-1.00)1.07 (1.02–1.12)**CTI-WC1.51 (1.49–1.52)***1.20 (1.17–1.23)***1.22 (1.19–1.25)***1.05 (1.02–1.08)***1.20 (1.15–1.25)***CTI-BMI1.45 (1.43–1.47)***1.16 (1.13–1.19)***1.24 (1.21–1.27)***1.04 (1.01–1.07)**1.17 (1.12–1.23)***CTI-WHtR1.53 (1.51–1.55)***1.24 (1.21–1.27)***1.24 (1.21–1.27)***1.05 (1.02–1.08)***1.21 (1.16–1.27)****P < 0.05; **P < 0.01; ***P < 0.001. HRs (95% CIs) are presented per 1-SD increase in each CTI-related measureModels were adjusted for age, sex, ethnicity, employment status, educational levels, Townsend deprivation index, frequency of drinking, smoking status, sleep duration, physical activity, and sedentary behaviorMASLD, metabolic dysfunction-associated steatotic liver disease; HR, hazard ratio; CI, confidence interval; SD, standard deviation; BMI, body mass index; CMM, cardiometabolic multimorbidity; CTI, C-reactive protein-triglyceride-glucose index; FCMD, first cardiometabolic disease; WC, waist circumference; WHtR, waist-to-height ratio Table 3Roles of CTI-related indices in transitions from healthy status to FCMD, CMM, and death among participants with MASLDExposureHR (95% CI)Transition AHealthy to FCMDTransition BHealthy to deathTransition CFCMD to CMMTransition DFCMD to deathTransition ECMM to deathNo. of transitions26,362/109,1816,674/109,1814,219/26,3624,406/26,3621,376/4,219Proportion, %24.26.116.016.732.6CTI1.41 (1.39–1.43)***1.11 (1.08–1.13)***1.17 (1.14–1.20)***0.98 (0.95-1.00)1.07 (1.02–1.12)**CTI-WC1.51 (1.49–1.52)***1.20 (1.17–1.23)***1.22 (1.19–1.25)***1.05 (1.02–1.08)***1.20 (1.15–1.25)***CTI-BMI1.45 (1.43–1.47)***1.16 (1.13–1.19)***1.24 (1.21–1.27)***1.04 (1.01–1.07)**1.17 (1.12–1.23)***CTI-WHtR1.53 (1.51–1.55)***1.24 (1.21–1.27)***1.24 (1.21–1.27)***1.05 (1.02–1.08)***1.21 (1.16–1.27)****P < 0.05; **P < 0.01; ***P < 0.001. HRs (95% CIs) are presented per 1-SD increase in each CTI-related measureModels were adjusted for age, sex, ethnicity, employment status, educational levels, Townsend deprivation index, frequency of drinking, smoking status, sleep duration, physical activity, and sedentary behaviorMASLD, metabolic dysfunction-associated steatotic liver disease; HR, hazard ratio; CI, confidence interval; SD, standard deviation; BMI, body mass index; CMM, cardiometabolic multimorbidity; CTI, C-reactive protein-triglyceride-glucose index; FCMD, first cardiometabolic disease; WC, waist circumference; WHtR, waist-to-height ratio Roles of CTI-related indices in transitions from healthy status to FCMD, CMM, and death among participants with MASLD *P < 0.05; **P < 0.01; ***P < 0.001. HRs (95% CIs) are presented per 1-SD increase in each CTI-related measure Models were adjusted for age, sex, ethnicity, employment status, educational levels, Townsend deprivation index, frequency of drinking, smoking status, sleep duration, physical activity, and sedentary behavior MASLD, metabolic dysfunction-associated steatotic liver disease; HR, hazard ratio; CI, confidence interval; SD, standard deviation; BMI, body mass index; CMM, cardiometabolic multimorbidity; CTI, C-reactive protein-triglyceride-glucose index; FCMD, first cardiometabolic disease; WC, waist circumference; WHtR, waist-to-height ratio Disease-specific transition analyses showed heterogeneous patterns according to the type of FCMD (Table 4). T2DM was the most common FCMD, followed by IHD and stroke. CTI-related indices showed the strongest associations with incident T2DM, particularly for CTI-WHtR and CTI-WC. For progression from FCMD to CMM, associations were strongest for the IHD-to-CMM transition and weaker, although still significant, for the T2DM-to-CMM transition. Regarding mortality transitions, CTI-related indices were generally associated with higher risks of death after specific CMDs, although some associations were not statistically significant. Mortality risks also differed across FCMD subtypes, with the highest subsequent mortality observed among participants with stroke as the FCMD. Overall, CTI-WHtR showed the most consistent and strongest associations across most disease-specific transitions, followed by CTI-WC. Table 4Roles of CTI-related indices in disease-specific transitions from healthy status to CMDs, CMM, and death among participants with MASLDTransitionsNo. of transitionsProportion, %HR (95% CI)CTICTI-WCCTI-BMICTI-WHtRA1. Healthy to T2DM12,419/109,18111.41.76 (1.73–1.79)***1.83 (1.80–1.85)***1.74 (1.72–1.76)***1.90 (1.88–1.93)***A2. Healthy to Stroke2,777/109,1812.51.07 (1.03–1.11)***1.13 (1.08–1.17)***1.10 (1.06–1.15)***1.15 (1.11–1.20)***A3. Healthy to IHD11,166/109,18110.21.14 (1.12–1.17)***1.20 (1.18–1.23)***1.12 (1.10–1.14)***1.16 (1.14–1.19)***A4. Healthy to Death6,674/109,1816.11.10 (1.08–1.13)***1.20 (1.17–1.23)***1.15 (1.12–1.18)***1.24 (1.21–1.27)***B1. T2DM to CMM1,786/12,41914.41.06 (1.02–1.10)**1.13 (1.09–1.18)***1.14 (1.10–1.19)***1.14 (1.09–1.18)***B2. T2DM to Death1,602/12,41912.91.02 (0.98–1.07)1.10 (1.05–1.14)***1.07 (1.03–1.12)**1.10 (1.05–1.14)***C1. Stroke to CMM581/2,77720.91.33 (1.22–1.45)***1.39 (1.29–1.50)***1.39 (1.30–1.50)***1.41 (1.31–1.52)***C2. Stroke to Death726/2,77726.11.09 (1.01–1.18)*1.07 (0.99–1.16)1.15 (1.07–1.24)***1.11 (1.03–1.21)**D1. IHD to CMM1,852/11,16616.61.49 (1.42–1.56)***1.55 (1.48–1.61)***1.55 (1.49–1.61)***1.62 (1.55–1.69)***D2. IHD to Death2,078/11,16618.61.05 (1.00-1.10)1.23 (1.18–1.29)***1.20 (1.15–1.26)***1.24 (1.18–1.30)***E. CMM to Death1,376/4,21932.61.07 (1.02–1.12)**1.20 (1.14–1.25)***1.17 (1.11–1.22)***1.21 (1.15–1.26)****P < 0.05; **P < 0.01; ***P < 0.001. HRs (95% CIs) are presented per 1-SD increase in each CTI-related measureModels were adjusted for age, sex, ethnicity, employment status, educational levels, Townsend deprivation index, frequency of drinking, smoking status, sleep duration, physical activity, and sedentary behaviorMASLD, metabolic dysfunction-associated steatotic liver disease; CMDs, cardiometabolic diseases; CMM, cardiometabolic multimorbidity; CTI, C-reactive protein-triglyceride-glucose index; HR, hazard ratio; CI, confidence interval; SD, standard deviation; IHD, ischemic heart disease; T2DM, type 2 diabetes mellitus; BMI, body mass index; WC, waist circumference; WHtR, waist-to-height ratio Table 4Roles of CTI-related indices in disease-specific transitions from healthy status to CMDs, CMM, and death among participants with MASLDTransitionsNo. of transitionsProportion, %HR (95% CI)CTICTI-WCCTI-BMICTI-WHtRA1. Healthy to T2DM12,419/109,18111.41.76 (1.73–1.79)***1.83 (1.80–1.85)***1.74 (1.72–1.76)***1.90 (1.88–1.93)***A2. Healthy to Stroke2,777/109,1812.51.07 (1.03–1.11)***1.13 (1.08–1.17)***1.10 (1.06–1.15)***1.15 (1.11–1.20)***A3. Healthy to IHD11,166/109,18110.21.14 (1.12–1.17)***1.20 (1.18–1.23)***1.12 (1.10–1.14)***1.16 (1.14–1.19)***A4. Healthy to Death6,674/109,1816.11.10 (1.08–1.13)***1.20 (1.17–1.23)***1.15 (1.12–1.18)***1.24 (1.21–1.27)***B1. T2DM to CMM1,786/12,41914.41.06 (1.02–1.10)**1.13 (1.09–1.18)***1.14 (1.10–1.19)***1.14 (1.09–1.18)***B2. T2DM to Death1,602/12,41912.91.02 (0.98–1.07)1.10 (1.05–1.14)***1.07 (1.03–1.12)**1.10 (1.05–1.14)***C1. Stroke to CMM581/2,77720.91.33 (1.22–1.45)***1.39 (1.29–1.50)***1.39 (1.30–1.50)***1.41 (1.31–1.52)***C2. Stroke to Death726/2,77726.11.09 (1.01–1.18)*1.07 (0.99–1.16)1.15 (1.07–1.24)***1.11 (1.03–1.21)**D1. IHD to CMM1,852/11,16616.61.49 (1.42–1.56)***1.55 (1.48–1.61)***1.55 (1.49–1.61)***1.62 (1.55–1.69)***D2. IHD to Death2,078/11,16618.61.05 (1.00-1.10)1.23 (1.18–1.29)***1.20 (1.15–1.26)***1.24 (1.18–1.30)***E. CMM to Death1,376/4,21932.61.07 (1.02–1.12)**1.20 (1.14–1.25)***1.17 (1.11–1.22)***1.21 (1.15–1.26)****P < 0.05; **P < 0.01; ***P < 0.001. HRs (95% CIs) are presented per 1-SD increase in each CTI-related measureModels were adjusted for age, sex, ethnicity, employment status, educational levels, Townsend deprivation index, frequency of drinking, smoking status, sleep duration, physical activity, and sedentary behaviorMASLD, metabolic dysfunction-associated steatotic liver disease; CMDs, cardiometabolic diseases; CMM, cardiometabolic multimorbidity; CTI, C-reactive protein-triglyceride-glucose index; HR, hazard ratio; CI, confidence interval; SD, standard deviation; IHD, ischemic heart disease; T2DM, type 2 diabetes mellitus; BMI, body mass index; WC, waist circumference; WHtR, waist-to-height ratio Roles of CTI-related indices in disease-specific transitions from healthy status to CMDs, CMM, and death among participants with MASLD *P < 0.05; **P < 0.01; ***P < 0.001. HRs (95% CIs) are presented per 1-SD increase in each CTI-related measure Models were adjusted for age, sex, ethnicity, employment status, educational levels, Townsend deprivation index, frequency of drinking, smoking status, sleep duration, physical activity, and sedentary behavior MASLD, metabolic dysfunction-associated steatotic liver disease; CMDs, cardiometabolic diseases; CMM, cardiometabolic multimorbidity; CTI, C-reactive protein-triglyceride-glucose index; HR, hazard ratio; CI, confidence interval; SD, standard deviation; IHD, ischemic heart disease; T2DM, type 2 diabetes mellitus; BMI, body mass index; WC, waist circumference; WHtR, waist-to-height ratio Predictive performance of CTI-related indices for CMM incidence The incremental predictive value of CTI-related indices for incident CMM is shown in Table 5. Compared with the conventional model, the addition of each index significantly improved model discrimination. The C-index increased from 0.705 (95% CI: 0.698–0.713) in the conventional model to 0.731 (95% CI: 0.724–0.738) after adding CTI, 0.746 (95% CI: 0.739–0.753) after adding CTI-WC, 0.740 (95% CI: 0.733–0.747) after adding CTI-BMI, and 0.748 (95% CI: 0.741–0.755) after adding CTI-WHtR (all P < 0.001). Consistent statistically significant improvements in NRI and IDI were also observed for all indices. The largest NRI was observed for CTI-WC (0.221, 95% CI: 0.182–0.245), followed by CTI-WHtR (0.217, 95% CI: 0.184–0.242), CTI-BMI (0.198, 95% CI: 0.166–0.226), and CTI (0.158, 95% CI: 0.132–0.181). Similarly, the highest IDI was observed for CTI-WHtR (0.047, 95% CI: 0.039–0.053), followed by CTI-WC (0.045, 95% CI: 0.034–0.053), CTI-BMI (0.036, 95% CI: 0.029–0.044), and CTI (0.029, 95% CI: 0.024–0.037), all with P < 0.001. In additional analyses using SCORE2 as the base model, the addition of CTI-related indices also provided incremental predictive information for incident CMM, with CTI-WHtR and CTI-WC showing the greatest improvements in C-index, NRI, and IDI (Table S5). These findings suggest that CTI-related indices, especially CTI-WC and CTI-WHtR, may provide incremental predictive information, although the magnitude of improvement was modest. Table 5Incremental predictive value of CTI-related indices for CMM among participants with MASLDModelsC-index (95% CI)NRI (95% CI)IDI (95% CI)EstimateP valueEstimateP valueEstimateP valueConventional model (Reference)0.705 (0.698–0.713)-Ref-Ref-Conventional model + CTI0.731 (0.724–0.738)< 0.0010.158 (0.132–0.181)< 0.0010.029 (0.024–0.037)< 0.001Conventional model + CTI-WC0.746 (0.739–0.753)< 0.0010.221 (0.182–0.245)< 0.0010.045 (0.034–0.053)< 0.001Conventional model + CTI-BMI0.740 (0.733–0.747)< 0.0010.198 (0.166–0.226)< 0.0010.036 (0.029–0.044)< 0.001Conventional model + CTI-WHtR0.748 (0.741–0.755)< 0.0010.217 (0.184–0.242)< 0.0010.047 (0.039–0.053)< 0.001The conventional model included age, sex, ethnicity, employment status, educational levels, Townsend deprivation index, frequency of drinking, smoking status, sleep duration, physical activity, and sedentary behavior. C-index, NRI, and IDI were compared with the conventional modelMASLD, metabolic dysfunction-associated steatotic liver disease; CMM, cardiometabolic multimorbidity; CI, confidence interval; CTI, C-reactive protein-triglyceride-glucose index; IDI, integrated discrimination improvement; NRI, net reclassification improvement; BMI, body mass index; WC, waist circumference; WHtR, waist-to-height ratio Table 5Incremental predictive value of CTI-related indices for CMM among participants with MASLDModelsC-index (95% CI)NRI (95% CI)IDI (95% CI)EstimateP valueEstimateP valueEstimateP valueConventional model (Reference)0.705 (0.698–0.713)-Ref-Ref-Conventional model + CTI0.731 (0.724–0.738)< 0.0010.158 (0.132–0.181)< 0.0010.029 (0.024–0.037)< 0.001Conventional model + CTI-WC0.746 (0.739–0.753)< 0.0010.221 (0.182–0.245)< 0.0010.045 (0.034–0.053)< 0.001Conventional model + CTI-BMI0.740 (0.733–0.747)< 0.0010.198 (0.166–0.226)< 0.0010.036 (0.029–0.044)< 0.001Conventional model + CTI-WHtR0.748 (0.741–0.755)< 0.0010.217 (0.184–0.242)< 0.0010.047 (0.039–0.053)< 0.001The conventional model included age, sex, ethnicity, employment status, educational levels, Townsend deprivation index, frequency of drinking, smoking status, sleep duration, physical activity, and sedentary behavior. C-index, NRI, and IDI were compared with the conventional modelMASLD, metabolic dysfunction-associated steatotic liver disease; CMM, cardiometabolic multimorbidity; CI, confidence interval; CTI, C-reactive protein-triglyceride-glucose index; IDI, integrated discrimination improvement; NRI, net reclassification improvement; BMI, body mass index; WC, waist circumference; WHtR, waist-to-height ratio Incremental predictive value of CTI-related indices for CMM among participants with MASLD The conventional model included age, sex, ethnicity, employment status, educational levels, Townsend deprivation index, frequency of drinking, smoking status, sleep duration, physical activity, and sedentary behavior. C-index, NRI, and IDI were compared with the conventional model MASLD, metabolic dysfunction-associated steatotic liver disease; CMM, cardiometabolic multimorbidity; CI, confidence interval; CTI, C-reactive protein-triglyceride-glucose index; IDI, integrated discrimination improvement; NRI, net reclassification improvement; BMI, body mass index; WC, waist circumference; WHtR, waist-to-height ratio When evaluated as standalone predictors, CTI-WC and CTI-WHtR showed the highest discriminative ability for incident CMM compared to other indices (Fig. 5). Specifically, CTI-WC showed the highest C-index of 0.665 (95% CI: 0.657–0.674), followed closely by CTI-WHtR with a C-index of 0.664 (95% CI: 0.656–0.672). CTI and CTI-BMI showed relatively lower discriminative performance. Pairwise comparisons indicated no significant difference between CTI-WC and CTI-WHtR (P = 0.477). However, CTI-WC and CTI-WHtR both showed significantly higher C-index values than CTI and CTI-BMI (all P < 0.001). To facilitate clinical interpretation, ROC curve analyses identified optimal cutoff values of 9.641 for CTI, 989.874 for CTI-WC, 297.987 for CTI-BMI, and 5.745 for CTI-WHtR (Table S6). CTI-WC showed the highest Youden index, followed closely by CTI-WHtR (Table S6). These findings support the potential utility of CTI-WC and CTI-WHtR for risk stratification of incident CMM among individuals with MASLD, while also indicating that their standalone predictive performance remained moderate. Fig. 5Predictive performance of CTI-related indices for incident CMM among participants with MASLD. Abbreviations: MASLD, metabolic dysfunction-associated steatotic liver disease; CI, confidence interval; CMM, cardiometabolic multimorbidity; CTI, C-reactive protein-triglyceride-glucose index; BMI, body mass index; WC, waist circumference; WHtR, waist-to-height ratio. Predictive performance of CTI-related indices for incident CMM among participants with MASLD. Abbreviations: MASLD, metabolic dysfunction-associated steatotic liver disease; CI, confidence interval; CMM, cardiometabolic multimorbidity; CTI, C-reactive protein-triglyceride-glucose index; BMI, body mass index; WC, waist circumference; WHtR, waist-to-height ratio. Exploratory mediation analyses based on blood biomarkers We further examined whether biomarkers related to metabolism, systemic inflammation, liver function, and renal function might statistically account for the associations between CTI-related indices and incident CMM. After biomarker screening and FDR correction, biomarkers that showed significant and directionally consistent associations was retained for exploratory mediation analyses (Tables S7 and S8). Detailed mediation findings are summarized in Table S9 and Fig. 6. Specifically, metabolic biomarkers showed the largest contributions, with HbA1c consistently accounting for the greatest proportion of the associations (PM: 12.3%-28.1%), followed by HDL-C (12.3%-17.6%) and ApoA (6.5%-8.2%), all with FDR-adjusted P < 0.001. Among inflammatory markers, neutrophil count showed the strongest contribution (6.2%-7.4%), followed by WBC count (2.5%-2.8%) and monocyte count (1.3%-1.4%), all with FDR-adjusted P < 0.001. Liver function-related biomarkers, including ALT, ALP, and AST, and renal function-related biomarkers, including urate, cystatin C, and urea, also showed smaller but statistically significant contributions. Overall, these exploratory findings suggest that the associations between CTI-related indices and incident CMM among individuals with MASLD may be partly related to multiple biomarker domains, especially glycemic dysregulation, lipid metabolism, systemic inflammation, and hepatic and renal dysfunction. Fig. 6Exploratory mediation analyses of blood biomarkers in the associations of CTI-related indices with incident CMM among participants with MASLD. Notes: *FDR-adjusted P value < 0.05; **FDR-adjusted P value < 0.01; ***FDR-adjusted P value < 0.001. Models were adjusted for age, sex, ethnicity, employment status, educational levels, Townsend deprivation index, drinking frequency, smoking status, sleep duration, physical activity, and sedentary behavior. Abbreviations: FDR, false discovery rate; MASLD, metabolic dysfunction-associated steatotic liver disease; CTI, C-reactive protein-triglyceride-glucose index; CMM, cardiometabolic multimorbidity; ALP, alkaline phosphatase; ALT, alanine aminotransferase; ApoA, apolipoprotein A; ApoB, apolipoprotein B; AST, aspartate aminotransferase; GGT, gamma-glutamyltransferase; HbA1c, glycated hemoglobin; HDL-C, high-density lipoprotein cholesterol; IGF-1, insulin-like growth factor 1; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; WBC, white blood cell count; BMI, body mass index; WC, waist circumference; WHtR, waist-to-height ratio. Exploratory mediation analyses of blood biomarkers in the associations of CTI-related indices with incident CMM among participants with MASLD. Notes: *FDR-adjusted P value < 0.05; **FDR-adjusted P value < 0.01; ***FDR-adjusted P value < 0.001. Models were adjusted for age, sex, ethnicity, employment status, educational levels, Townsend deprivation index, drinking frequency, smoking status, sleep duration, physical activity, and sedentary behavior. Abbreviations: FDR, false discovery rate; MASLD, metabolic dysfunction-associated steatotic liver disease; CTI, C-reactive protein-triglyceride-glucose index; CMM, cardiometabolic multimorbidity; ALP, alkaline phosphatase; ALT, alanine aminotransferase; ApoA, apolipoprotein A; ApoB, apolipoprotein B; AST, aspartate aminotransferase; GGT, gamma-glutamyltransferase; HbA1c, glycated hemoglobin; HDL-C, high-density lipoprotein cholesterol; IGF-1, insulin-like growth factor 1; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; WBC, white blood cell count; BMI, body mass index; WC, waist circumference; WHtR, waist-to-height ratio. Sensitivity and subgroup analyses The associations between CTI-related indices and incident CMM remained robust across multiple sensitivity analyses. Specifically, associations were largely unchanged after excluding participants who developed CMM within the first 5 years of follow-up (Table S10), imputing missing covariate data (Table S11), accounting for the competing risk of non-CMM-related death (Table S12), further adjusting for baseline hypoglycemic and lipid-lowering medication use, healthy diet score, genetic risk, and family history of CMDs (Tables S13 and S14), and applying a broader CMM definition that additionally included hypertension (Table S15). Stratified analyses by sociodemographic factors further indicated that the associations were generally comparable across subgroups (Table S16). Discussion In this large prospective cohort study of more than 100,000 individuals with MASLD, all four CTI-related indices, including CTI, CTI-BMI, CTI-WC, and CTI-WHtR, were positively associated with the risk of incident CMM during extended follow-up. These associations were particularly pronounced for CTI-WC and CTI-WHtR. CTI-related indices also provided modest incremental predictive information beyond traditional risk factors, with CTI-WC and CTI-WHtR showing relatively better discrimination and risk reclassification performance. In multi-state analyses, CTI-related indices were associated with multiple stages of CMM progression, especially the transition from baseline to T2DM and from IHD to CMM. Exploratory biomarker analyses further suggested that metabolic dysfunction, particularly glycemic and lipid abnormalities, together with systemic inflammation and liver and kidney dysfunction, may statistically account for part of the observed associations. MASLD and CMDs share several pathophysiological features, including IR, chronic low-grade inflammation, and metabolic dysregulation [10, 11]. Therefore, identifying accessible markers that capture cardiometabolic risk among individuals with MASLD is important. Previous studies have reported associations of CTI with individual CMDs, including CVD and T2DM [21–32], and more recent evidence has linked CTI to MASLD and mortality outcomes among individuals with MASLD [34–36]. However, most prior studies focused on single outcomes and did not address CMM, which better reflects the tendency of cardiometabolic conditions to cluster and progress over time. In the present study, elevated baseline CTI-related indices were consistently associated with increased CMM risk, whether modeled as continuous variables or quartile categories. These findings extend previous evidence from individual CMDs and general-population CMM studies [37–42] to individuals with MASLD, a population at high cardiometabolic risk. Among the four indices, CTI-WC and CTI-WHtR showed the strongest associations with incident CMM. This may reflect the added value of incorporating central adiposity into an integrated inflammatory-metabolic marker. Central obesity is closely related to IR, systemic inflammation, hepatic steatosis, and adverse cardiometabolic profiles, all of which are highly relevant to MASLD and CMM development [3, 10, 11]. In the exploratory prediction analyses, CTI-WHtR and CTI-WC also yielded relatively greater and statistically significant improvements in the C-index, NRI, and IDI. However, the absolute improvements were modest. Therefore, these findings should be interpreted as preliminary evidence for potential risk stratification rather than as proof of immediate clinical utility. Our findings are consistent with previous studies showing that TyG-related indices combined with adiposity measures, particularly TyG-WC and TyG-WHtR, may improve cardiometabolic risk assessment among individuals with MASLD [17, 43–46]. Supporting and extending early evidence, our findings suggest that CTI-related indices, particularly CTI-WHtR and CTI-WC, may provide complementary information for identifying individuals with MASLD at elevated risk of CMM. This interpretation was further supported by additional analyses using SCORE2 as the base model, in which CTI-WHtR and CTI-WC still showed the greatest incremental improvements. Nevertheless, improvements in predictive metrics do not necessarily translate into clinical benefit, as the C-index, NRI, and IDI do not directly assess clinical utility. Further studies are needed to externally validate the results, evaluate calibration and clinical net benefit, and determine whether CTI-related indices can improve prevention strategies in individuals with MASLD. Similarly, the cutoff values derived from the Youden index should be regarded as data-driven exploratory thresholds rather than definitive clinical decision limits. A major contribution of this study is the use of multi-state models to examine the association of CTI-related indices with the dynamic progression of CMM in individuals with MASLD. Prior studies have mainly evaluated single disease endpoints [21–32], whereas CMM usually develops through a progressive process from a CMD-free state to FCMD, CMM, and death. Our findings indicated that higher CTI-related indices were associated with increased risks of most transitions, with stronger associations generally observed for CTI-WHtR and CTI-WC. The associations were most pronounced for the transition from baseline to FCMD, particularly T2DM, suggesting that CTI-related indices may be more strongly related to early cardiometabolic deterioration. This finding is biologically plausible because IR, a core component reflected by the TyG index, is directly involved in the development of T2DM. For transitions from FCMD to CMM, the strongest associations were observed among participants with IHD. Among patients who already have IHD, elevated CTI-related indices may indicate a broader cardiometabolic disturbance involving IR, inflammation, dyslipidemia, and central obesity, which may accelerate the development of additional CMDs. These findings are broadly consistent with previous multi-state studies of CTI or TyG-related indices [39, 50, 70]. Consistent with previous research [39], we failed to observe significant associations between CTI and transitions from individual CMDs (e.g., T2DM and IHD) to death. However, when combined with adiposity measures, these CTI-related indices showed generally significant associations with these transitions, emphasizing the importance of incorporating adiposity into risk assessment and highlighting the joint contribution of inflammation, IR, and obesity to mortality risk in patients with CMDs. In summary, our multi-state analyses provide a more comprehensive understanding of the dynamic associations between CTI-related indices and CMM progression among individuals with MASLD, suggesting that CTI-related indices, particularly CTI-WHtR and CTI-WC, may help identify high-risk individuals at different stages of CMM progression. From a clinical translation perspective, CTI-WHtR and CTI-WC may serve as practical preliminary tools for risk stratification among individuals with MASLD, as they can be calculated using routinely available inflammatory, metabolic, and anthropometric parameters. Individuals with elevated CTI-WHtR or CTI-WC, particularly those above the exploratory cutoff values identified in our study, may warrant more comprehensive cardiometabolic evaluation and closer follow-up. For individuals who have already developed a FCMD, these indices may also help identify those at higher risk of progression to CMM. However, this proposed application should be considered a risk-enrichment strategy rather than a definitive clinical decision pathway, and further external validation and clinical utility assessment are required before routine implementation. The biological domains underlying the associations between CTI-related indices and CMM remain incompletely understood. TyG, as a surrogate marker of IR, may reflect metabolic disturbances related to endothelial dysfunction, oxidative stress, and dysregulated lipid metabolism [71–73], which may promote the development and coexistence of CMDs [72–74]. CRP, as a marker of systemic inflammation, may reflect inflammatory processes involved in vascular dysfunction and atherosclerotic progression [75, 76]. However, mechanisms inferred from individual components of CTI may not fully explain the associations observed for integrated CTI-related indices. The biomarker domains through which CTI-related indices, as integrated indicators, are associated with CMM risk remain unclear. In this study, we used an exploratory mediation framework to evaluate whether circulating biomarkers might statistically account for part of these associations. Biomarkers related to metabolic status showed the largest contributions, particularly HbA1c and HDL-C. Supporting our findings, a large cohort study based on MASLD patients reported that HbA1c statistically accounted for the association between CTI and all-cause mortality [36]. Furthermore, systemic inflammatory biomarkers, particularly neutrophils, showed notable contributions. In line with our findings, Assempoor et al. suggested that inflammatory markers, including neutrophils, may partly explain the elevated mortality risk associated with CTI [36]. Finally, biomarkers reflecting organ dysfunction, particularly those related to liver (ALT, ALP, and AST) and renal function (urate and cystatin C), also showed modest but statistically significant contributions. Similar to our findings, associations of CTI with liver and kidney diseases or related functional abnormalities have previously been reported [48, 49]. A large-scale cohort study has likewise suggested that dysregulation of liver and renal function-related biomarkers may partially account for the associations between TyG-related indices and CMM [50]. Collectively, these exploratory findings extend existing evidence by identifying several biomarker domains that may be related to the association between CTI-related indices and incident CMM among individuals with MASLD. Nevertheless, given the generally low-to-moderate mediating proportions, these results should not be interpreted as clearly delineating key pathogenic pathways or establishing definitive causal mechanisms. Rather, they identify several potentially relevant biomarker domains and provide preliminary clues for future mechanistic research with repeated biomarker assessments, stronger temporal resolution, and experimental designs. This study has several strengths, including its prospective design, large sample size, extended follow-up, comprehensive adjustment for potential confounders, multi-state modeling of CMM progression, and exploratory evaluation of circulating biomarkers. Nevertheless, several limitations should be considered. First, the UK Biobank has a low participation rate and is subject to potential healthy volunteer bias, which may limit representativeness and affect the generalizability of absolute risk estimates. However, our study primarily examined prospective associations rather than estimating disease incidence, and associations between risk factors and outcomes in this cohort have generally been shown to be externally applicable [77]. Second, the study population was predominantly White and relatively ethnically homogeneous, which may restrict the generalizability and global applicability of our findings. In addition, all analyses were based on a single database. Although sensitivity and subgroup analyses supported the internal robustness of our findings, validation in independent, multi-center, and ethnically diverse cohorts is needed to confirm their reproducibility and generalizability. Third, MASLD was identified using an FLI-based definition rather than liver imaging or histopathological assessment. Although FLI is a validated non-invasive surrogate marker for hepatic steatosis and has been used in previous UK Biobank studies of MASLD [17, 53, 55], disease misclassification cannot be excluded, and FLI does not provide information on steatosis severity, steatohepatitis, or fibrosis. Further studies using imaging- or pathology-confirmed MASLD are warranted. Fourth, the observational nature of this study precludes causal inference. Although the prospective design may reduce reverse causality, residual and unmeasured confounding cannot be completely excluded. Although we conducted sensitivity analyses adjusting for baseline use of hypoglycemic and lipid-lowering medications, healthy diet score, genetic risk, and family history of CMDs, residual confounding may still be present. In particular, lifestyle factors and medication use may change during follow-up, and the effects of other medications, such as hepatoprotective agents, were not fully captured. Fifth, CTI-related indices were assessed only once at baseline, limiting the evaluation of dynamic changes and cumulative exposure. Sixth, although the CMM definition used in the main analyses is commonly adopted in previous studies [9, 39, 50], it may not fully capture the broader spectrum of clinical phenotypes. Nevertheless, sensitivity analyses additionally including hypertension yielded broadly consistent results. Also, CMD outcomes and transition states were primarily ascertained using ICD-10 codes, which may introduce diagnostic misclassification and affect transition timing in the multistate models. Seventh, although CTI-related indices improved several prediction metrics, the absolute improvements were modest and do not establish clinical utility. Although sensitivity analyses suggested that CTI-WHtR and CTI-WC provided additional predictive information beyond SCORE2, comprehensive head-to-head comparisons with other classic metabolic-inflammatory indicators, and formal health economic evaluations were not conducted. Therefore, these findings should be interpreted as exploratory evidence for potential risk stratification rather than clinical superiority or implementation value. Further studies are needed to externally validate these results, assess calibration and clinical net benefit, and determine whether CTI-related indices can improve screening efficiency, prevention strategies, or patient outcomes. Finally, despite prospective outcome ascertainment, exposures and candidate mediators were assessed only once at baseline, which constrains evaluation of temporal ordering required for causal mediation analysis. Accordingly, the mediation findings should be interpreted as exploratory and hypothesis-generating rather than as evidence of definitive causal pathways. Future studies should incorporate repeated measurements of CTI-related indices and relevant biomarkers to better characterize longitudinal exposure patterns and to strengthen the evaluation of temporal ordering and mediation assumptions. Conclusions In this large prospective cohort of individuals with MASLD, CTI-related indices were significantly associated with a higher risk of incident CMM. CTI-WC and CTI-WHtR showed stronger associations and relatively better predictive performance than the other indices. Moreover, these indices exhibited stage-specific associations across the development and progression of CMM, with CTI-WHtR and CTI-WC showing consistently stronger associations across most transitions. Exploratory mediation analyses suggested that the associations between CTI-related indices and incident CMM may be partly related to metabolic dysregulation, systemic inflammation, and hepatic and renal dysfunction. Although CTI-related indices provided statistically significant incremental predictive information, the magnitude of improvement was modest. Therefore, CTI-WC and CTI-WHtR may serve as complementary markers for cardiometabolic risk stratification in individuals with MASLD, but further external validation and clinical utility assessment are warranted. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1